Skip to main navigation Skip to search Skip to main content

Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion

  • Raul D. Santos
  • , Alberto Lorenzatti
  • , Pablo Corral
  • , Juan Patricio Nogueira
  • , Alberto M. Cafferata
  • , Daniel Aimone
  • , Charles M. Lourenço
  • , Maria Cristina Izar
  • , Josivan G. Lima
  • , Ana Maria Lottenberg
  • , Rodrigo Alonso
  • , Karla Garay
  • , Alvaro Ruiz Morales
  • , Hernando Vargas-Uricoechea
  • , Christian A.Colón Peña
  • , Alejandro Roman-González
  • Universidade de São Paulo
  • Hospital Israelita Albert Einstein
  • Rusculleda Foundation for Research
  • FASTA University
  • Universidad Nacional de Formosa, Facultad de Ciencias de la Salud
  • Universidad del Salvador
  • Universidad Nacional de La Plata
  • Centro Universitario Estacio de Ribeirao Preto
  • Universidade Federal de São Paulo
  • Universidade Federal do Rio Grande do Norte
  • Center for Advanced Metabolic Medicine and Nutrition
  • Hospital Carlos Andrade Marin
  • Universidad del Cauca
  • Hospital Universitario Fundación Santa Fe
  • Universidad de Antioquia

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by extremely high triglyceride levels due to impaired clearance of chylomicrons from plasma. This paper is the result of a panel discussion with Latin American specialists who raised the main issues on diagnosis and management of FCS in their countries. Overall FCS is diagnosed late on the course of the disease, is characterized by heterogeneity on the occurrence of pancreatitis, and remains a long time in care of different specialists until reaching a lipidologist. Pancreatitis and secondary diabetes are frequently seen, often due to late diagnosis and inadequate care. Molecular diagnosis is unusual; however, loss of function variants on the lipoprotein lipase gene are apparently the most frequent etiology. A founder effect of the glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 gene has been described in the northeast of Brazil. Low awareness of the disease amongst health professionals contributes to inadequate care and an inadequate patient journey.

Original languageEnglish
Pages (from-to)620-624
Number of pages5
JournalJournal of Clinical Lipidology
Volume15
Issue number5
DOIs
StatePublished - 01 Sep 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Clinical phenotype
  • FCS
  • Familial chylomicronemia syndrome
  • Hypertriglyceridemia

Fingerprint

Dive into the research topics of 'Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion'. Together they form a unique fingerprint.

Cite this